Impact of right heart function and pulmonary venous Hypertension on CRT Response in patients with left ventricular dysfunction and dyssynchrony

Conditions

I50

Alexander Schmeißer, Thomas Rauwolf, Thomas Groscheck, Ivan Tanev, Marco Bo Hansen et al. (8 authors)

European Heart Journal2020-11-011 citations

10.1093/ehjci/ehaa946.1903

Pressure–volume loop validation of TAPSE/PASP for right ventricular arterial coupling in heart failure with pulmonary hypertension

Alexander Schmeißer, Thomas Rauwolf, Thomas Groscheck, Siegfried Kropf, Blerim Luani et al. (10 authors)

European Heart Journal - Cardiovascular Imaging2020-10-0583 citations

10.1093/ehjci/jeaa285

P4687Relevance of TAPSE and FAC, and their relationship to PASP as echo-derived measures for RV-PA coupling in heart failure: a comparative analysis with invasive RV-pressure volume loop data

Alexander Schmeißer, Thomas Rauwolf, Ali Ghanem, J Handerer, Katharina Fischbach et al. (12 authors)

European Heart Journal2019-10-011 citations

10.1093/eurheartj/ehz745.1068

Right heart function interacts with left ventricular remodeling after CRT: A pressure volume loop study.

Schmeisser A, Rauwolf T, Ghanem A, Groscheck T, Adolf D, Grothues F, Fischbach K, Kosiek O, Huth C, Kropf S, Lange S, Luani B, Smid J, Schäfer MH, Schreiber J, Tanev I, Wengler F, Yeritsyan NB, Steendijk P, Braun-Dullaeus RC.

2018-03-0810 citations

10.1016/j.ijcard.2018.03.026

Interventions

Group 1: Examination of right heart function as a predictor for the cardiac resynchronization therapy in patients with left heart failure

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Patients with heart failure symptoms lasting at least 6 weeks (according to the current guidelines for CRT treatment of chronic heart failure) 2. At least 18 years of age 3. Medical need for implants (implants based on the standard implant guidelines from the European Society of Cardiology (ESC)) 4. Left ventricular ejection fraction (LVEF) 130 ms 7. Medical therapy, unless contraindicated, includes - ACE inhibitor or - AT1 blocker given for at least one month before enrolment, - Beta-blocker started at least 3 months before enrolment, - aldosterone antagonist Dosage of therapies mentioned above must be unchanged for at least one month. 8. The patient must have given its written informed consent to participate in the study after receiving adequate previous information and prior to any study specific procedures.

Exclusion criteria

Exclusion criteria: 1. Life expectancy < 12 months 2. Pregnancy (routine test before left and right heart catheter examination) 3. Prior CRT 4. Atrial arrhythmias 5. Right bundle branch block 6. QRS < 130 ms 7. Heart failure requiring continuous intravenous therapy 8. Patients with acute coronary syndromes or coronary revascularization within 4 months before CRT

Design outcomes

Primary

Measure	Time frame
To test whether parameters of right ventricular function, morphology and pulmonary hemodynamic are able to predict the clinical outcome and the remodeling of the right and left ventricle after CRT. positive echocardiographic response (reduction of LVESV) to CRT within 6 month follow-up (primary); positive clinical response to CRT measured by clinical response score (co-primary),	—

Secondary

Measure	Time frame
positive clinical response to CRT measured in terms of quality of life	—

Countries

Germany

Contacts

Public ContactJan Smid

Universitätsklinikum Magdeburg, Klinik für Kardiologie

jan.smid@med.ovgu.de0391-6715190

Outcome results

None listed